JP2008512356A5 - - Google Patents

Download PDF

Info

Publication number
JP2008512356A5
JP2008512356A5 JP2007525706A JP2007525706A JP2008512356A5 JP 2008512356 A5 JP2008512356 A5 JP 2008512356A5 JP 2007525706 A JP2007525706 A JP 2007525706A JP 2007525706 A JP2007525706 A JP 2007525706A JP 2008512356 A5 JP2008512356 A5 JP 2008512356A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007525706A
Other languages
Japanese (ja)
Other versions
JP2008512356A (en
Filing date
Publication date
Priority claimed from US10/916,155 external-priority patent/US7666979B2/en
Application filed filed Critical
Publication of JP2008512356A publication Critical patent/JP2008512356A/en
Publication of JP2008512356A5 publication Critical patent/JP2008512356A5/ja
Withdrawn legal-status Critical Current

Links

Description

Figure 2008512356
Figure 2008512356

Figure 2008512356
Figure 2008512356

JP2007525706A 2004-08-11 2005-08-09 Process for the production of multivalent constructs for therapeutic and diagnostic applications Withdrawn JP2008512356A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/916,155 US7666979B2 (en) 2002-03-01 2004-08-11 Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
PCT/US2005/028127 WO2006096207A2 (en) 2004-08-11 2005-08-09 Methods for preparing multivalent constructs for therapeutic and diagnostic applications

Publications (2)

Publication Number Publication Date
JP2008512356A JP2008512356A (en) 2008-04-24
JP2008512356A5 true JP2008512356A5 (en) 2008-09-04

Family

ID=36953780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007525706A Withdrawn JP2008512356A (en) 2004-08-11 2005-08-09 Process for the production of multivalent constructs for therapeutic and diagnostic applications

Country Status (6)

Country Link
US (1) US7666979B2 (en)
EP (1) EP1778299A4 (en)
JP (1) JP2008512356A (en)
AU (1) AU2005328644A1 (en)
CA (1) CA2575730A1 (en)
WO (1) WO2006096207A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
CA2418229A1 (en) * 2002-05-16 2003-11-16 Rohan Dharmakumar Microbubble construct for sensitivity enhanced mr manometry
CN103204911B (en) * 2005-12-09 2015-04-01 布拉科瑞士有限公司 Targeting Vector-phospholipid Conjugates
WO2008075968A1 (en) * 2006-12-20 2008-06-26 Ge Healthcare As Contrast agents
US8535639B2 (en) * 2007-07-17 2013-09-17 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Trifunctional imaging agent for monoclonal antibody tumor-targeted imaging
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
US8834839B2 (en) 2009-04-27 2014-09-16 General Electric Company Labeled molecular imaging agents, methods of making and methods of use
CN102869384B (en) 2009-06-22 2016-01-13 伯纳姆医学研究所 Use the method and composition with the peptides and proteins of C-end element
CA2779730C (en) 2009-11-05 2019-04-30 University Of Virginia Patent Foundation Compositions and methods for detecting plectin-1 as a biomarker for cancer
HUE039009T2 (en) 2011-08-05 2018-12-28 Res Found Dev Improved methods and compositions for modulation of olfml3 mediated angiogenesis
US8784774B2 (en) 2011-09-16 2014-07-22 General Electric Company Labeled molecular imaging agents and methods of use
US9057712B1 (en) 2011-10-27 2015-06-16 Copilot Ventures Fund Iii Llc Methods of delivery of encapsulated perfluorocarbon taggants
US9606123B2 (en) 2013-03-29 2017-03-28 University Of Virginia Patent Foundation Compositions and methods for diagnosing and monitoring ovarian cancer progression and treatment
US9468692B2 (en) 2014-01-23 2016-10-18 General Electric Company Labeled molecular imaging agents and methods of use
US9468693B2 (en) 2014-01-23 2016-10-18 General Electric Company Labeled molecular imaging agents and methods of use
JP6099055B2 (en) * 2014-05-09 2017-03-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Fucoidan as a ligand for the diagnosis of degenerative lesions
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
WO2017192598A1 (en) * 2016-05-02 2017-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Pre-targeting strategies for molecular imaging and/or radioimmunotherapy
US11007272B1 (en) 2016-10-07 2021-05-18 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections
WO2018222987A1 (en) * 2017-06-01 2018-12-06 Tarveda Therapeutics, Inc. Targeted constructs
AU2018287171B2 (en) 2017-06-21 2024-03-28 Glykos Finland Oy Hydrophilic linkers and conjugates thereof
CN109407133B (en) * 2017-08-18 2023-09-22 南京中硼联康医疗科技有限公司 Biological dosimeter and neutron capture treatment system with same
CA3118523A1 (en) 2018-12-18 2020-06-25 Bracco Suisse Sa Optimized process for dimeric peptide-phospholipid conjugate
CN112295551B (en) * 2020-10-10 2022-11-29 韶关学院医学院 Mn-doped ZnS quantum dot fluorescent molecularly imprinted polymer and application thereof
CN113845606B (en) * 2021-09-28 2022-12-16 称意科技研发园(江苏)有限公司 Modified cyclodextrin dye adsorbent and preparation method thereof
US12006339B2 (en) 2022-05-20 2024-06-11 Navidea Biopharmaceuticals, Inc. CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker
WO2024077062A2 (en) * 2022-10-05 2024-04-11 The Medical College Of Wisconsin, Inc. Mitochondria-targeted n-acetylcysteine and analogs

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913451A (en) * 1957-04-04 1959-11-17 Mallinckrodt Chemical Works Iodophenylamidoalkanesulfonic acid compounds
US5700444A (en) * 1992-02-20 1997-12-23 Rhomed Incorporated Chemotactic peptide pharmaceutical applications
US5759515A (en) * 1989-08-09 1998-06-02 Rhomed Incorporated Polyvalent peptide pharmaceutical applications
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US6146657A (en) * 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5305757A (en) * 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US20020032313A1 (en) 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
OA10149A (en) * 1991-03-29 1996-12-18 Genentech Inc Vascular endothelial cell growth factor antagonists
US5205290A (en) * 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5861301A (en) * 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
WO1993022343A1 (en) * 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
US6824777B1 (en) * 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
HU221343B1 (en) 1992-10-28 2002-09-28 Genentech Inc Use of anti-vegf antibodies for the treatment of cancer
DE69434538T2 (en) * 1994-03-08 2006-08-10 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6221839B1 (en) * 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6403088B1 (en) * 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6245530B1 (en) * 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
JP4215820B2 (en) 1995-06-07 2009-01-28 イマアーレクス・フアーマシユーチカル・コーポレーシヨン Novel targeted compositions for diagnostic and therapeutic uses
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6231834B1 (en) * 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6521211B1 (en) * 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US7423125B2 (en) * 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6361946B1 (en) * 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
PT848755E (en) * 1995-09-08 2003-12-31 Genentech Inc PROTEIN RELATED TO VEGF
EP1007101B1 (en) 1996-10-28 2006-05-17 GE Healthcare AS Improvements in or relating to diagnostic/therapeutic agents
US6331289B1 (en) * 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6261537B1 (en) * 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
CA2270120A1 (en) * 1996-10-28 1998-05-07 Pal Rongved Improvements in or relating to diagnostic/therapeutic agents
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
US7125714B2 (en) * 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US20020010137A1 (en) * 1997-09-18 2002-01-24 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6245318B1 (en) * 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
ATE371727T1 (en) * 1997-06-18 2007-09-15 Merck & Co Inc KDR, A HUMAN TYROSINE KINASE RECEPTOR
US6777534B1 (en) * 1997-12-09 2004-08-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
IL138214A0 (en) * 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6524553B2 (en) * 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
BR9909420A (en) 1998-03-31 2001-09-25 Du Pont Pharm Co Compound, kit, diagnostic or therapeutic metallopharmaceutical composition, ultrasound contrast agent composition, therapeutic radiopharmaceutical composition and diagnostic radiopharmaceutical composition
US6537520B1 (en) * 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6548663B1 (en) * 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6548048B1 (en) * 1998-04-28 2003-04-15 Amersham Health As Lipopeptide stabilized microbubbles as diagnostic/therapeutic agents
US20030236190A1 (en) * 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US7173005B2 (en) * 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
DE19941092A1 (en) 1999-08-30 2001-03-01 Philips Corp Intellectual Pty Network with an identifier reduction
AU783683B2 (en) * 2000-01-18 2005-11-24 Vegenics Limited VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
JP2003528824A (en) * 2000-02-04 2003-09-30 スプラテック ファーマ インコーポレイティド Ligand for vascular endothelial growth factor receptor
WO2001064235A1 (en) * 2000-03-02 2001-09-07 Ludwig Institute For Cancer Research Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d
EP1519193B1 (en) 2000-03-02 2011-11-09 Vegenics Pty Ltd Methods for detecting cancers expressing vascular endothelial growth factor D
US20020102260A1 (en) * 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
US20010031485A1 (en) * 2000-03-22 2001-10-18 Sibtech, Inc. Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
JP2003528632A (en) * 2000-03-31 2003-09-30 インスティティ・パスツール Peptide inhibiting vascular endothelial growth factor (VEGF) -mediated angiogenesis, polynucleotide encoding the peptide and methods of use
AU6456501A (en) * 2000-05-03 2001-11-12 Ludwig Inst Cancer Res A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
EP1166798A1 (en) 2000-06-23 2002-01-02 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use
KR20030036238A (en) 2000-06-23 2003-05-09 쉐링 악티엔게젤샤프트 Combinations and Compositions Which Interfere with VEGF/VEGF and Angiopoietin/Tie Receptor Function and Their Use (II)
EP1166799A1 (en) 2000-06-28 2002-01-02 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)
WO2002007747A1 (en) * 2000-07-18 2002-01-31 Joslin Diabetes Center, Inc. Methods of modulating fibrosis
US20020091082A1 (en) * 2000-09-13 2002-07-11 Aiello Lloyd P. Methods of modulating symptoms of hypertension
US20030082103A1 (en) * 2000-10-11 2003-05-01 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
US20020091567A1 (en) * 2001-01-09 2002-07-11 Royston Tymarshall E. System and method for electronically redeeming coupons
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
WO2002072011A2 (en) * 2001-03-08 2002-09-19 Targesome, Inc. Stabilized therapeutic and imaging agents
WO2002083849A2 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
EP1456240A4 (en) * 2001-10-24 2006-08-09 Antyra Inc Target specific screening and its use for identifying target binders
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
CA2477935C (en) * 2002-03-01 2015-01-06 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
EP2301587B1 (en) * 2002-03-01 2014-06-25 Dyax Corp. KDR and VEGF/KDR binding peptides and their use in diagnosis
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US20040033949A1 (en) * 2002-05-06 2004-02-19 Genentech, Inc. Use of VEGF for treating bone defects
US20040212193A1 (en) 2002-10-08 2004-10-28 Johnstone Ian David Connector
NO20026286D0 (en) 2002-12-30 2002-12-30 Amersham Health As New peptides
NO20026285D0 (en) 2002-12-30 2002-12-30 Amersham Health As New peptides
US7183256B2 (en) * 2003-03-21 2007-02-27 Cleveland Clinic Foundation TIMP3 as VEGF inhibitor
US7601341B2 (en) * 2003-06-05 2009-10-13 Research Development Foundation Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
WO2005016963A2 (en) 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Heparin binding veger-3 ligands
US20050043235A1 (en) 2003-06-12 2005-02-24 Kari Alitalo Use of VEGF-C or VEGF-D in reconstructive surgery
JP2005110508A (en) 2003-10-02 2005-04-28 Nec Soft Ltd Growth factor-like protein derived from snake venom having specific binding property to vascular endothelial growth factor receptor 2
EP1715897B2 (en) 2004-01-20 2013-10-30 Sunnybrook and Women's College Health Sciences Centre High frequency ultrasound imaging using contrast agents
US8067368B2 (en) 2004-01-27 2011-11-29 The Ohio State University Research Foundation Vascular endothelial growth factors and methods of their use
JP2008509157A (en) 2004-08-06 2008-03-27 ソフェリオン セラピューティクス,インコーポレイテッド Anti-angiogenic peptides and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2008512356A5 (en)
JP2008512492A5 (en)
JP2008512398A5 (en)
JP2006257115A5 (en)
JP2007516202A5 (en)
JP2006045672A5 (en)
JP2006063441A5 (en)
JP2005261231A5 (en)
JP2007514712A5 (en)
JP2007119645A5 (en)
JP2008525570A5 (en)
JP2007321035A5 (en)
JP2007231207A5 (en)
JP2008524415A5 (en)
JP2006273834A5 (en)
JP2007190226A5 (en)
JP2008525527A5 (en)
JP2007001784A5 (en)
JP2005120465A5 (en)
JP2007153801A5 (en)
JP2007254440A5 (en)
JP2007537849A5 (en)
JP2005095148A5 (en)
JP2006289212A5 (en)
JP2007526266A5 (en)